Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder.
OBJECTIVE
It has previously been shown that glucose uptake and use is more prevalent in carcinomas than in normal cells and tissues. We hypothesized that human erythrocyte glucose transporter (Glut-1) expression is increased in bladder transitional cell carcinoma (TCC) and that the grade of expression might correlate with the degree of malignancy.


METHODS
Immunostaining of Glut-1 protein was studied in normal bladder (5 cases), benign papilloma (10 cases), superficial tumor (48 cases), and invasive tumor (31 cases) tissue. The immunoreactivity grading system used was as follows: absence of immunoreactivity in tumor cell = 0; less than 10% of the tumor cells immunoreactive = 1+; 10% to 50% of the tumor cells immunoreactive = 2+; and greater than 50% of the tumor cells immunoreactive = 3+.


RESULTS
Immunostaining of Glut-1 protein was not expressed in the normal bladder or benign papilloma samples, but it was expressed in 63.0% (46 of 73) of the TCC samples. In the pattern of expression of Glut-1 protein, superficial TCC was stained focally, but invasive TCC was stained diffusely in the tumor nests. The grade of Glut-1 protein expression increased more significantly in the invasive TCC than in the superficial TCC samples (P = 0.002) and more significantly in the high nuclear grade than in the low nuclear grade samples (P = 0.007). In the superficial TCC samples, the bladder tumor recurrence rate did not significantly correlate with Glut-1 protein expression (P = 0.40).


CONCLUSIONS
Our results suggest that the Glut-1 protein is not expressed in normal bladder mucosa and benign lesions, that Glut-1 protein expression is strongly associated with neoplastic progression in bladder TCC, and that Glut-1 expression does not correlate with the recurrence rate in superficial bladder TCC.
Chang
S
S
Department of Urology Kyung Hee University School of Medicine, Seoul, South Korea.
Lee
S
S
Lee
C
C
Kim
J I
JI
Kim
Y
Y
D002295:Carcinoma, Transitional Cell / Q000737:chemistry* / Q000473:pathology; D051272:Glucose Transporter Type 1; D006801:Humans; D007150:Immunohistochemistry; D009004:Monosaccharide Transport Proteins / Q000378:metabolism*; D009092:Mucous Membrane / Q000737:chemistry; D010212:Papilloma / Q000737:chemistry; D018308:Papilloma, Inverted / Q000737:chemistry; D001743:Urinary Bladder / Q000737:chemistry; D001749:Urinary Bladder Neoplasms / Q000737:chemistry* / Q000473:pathology
D051272:Glucose Transporter Type 1; D009004:Monosaccharide Transport Proteins; C495677:SLC2A1 protein, human